In previous studies, elevated expression of ENO1 was positively associated with progression and poor prognosis in neuroendocrine tumors, neuroblastoma, pancreatic cancer, prostate cancer, cholangiocarcinoma, thyroid carcinoma, lung cancer, hepatocellular carcinoma and breast cancer, and suggested an involvement between ENO1 and tumor progression [45–51]. This evidence concerns the gene ENO1 and neuroendocrine neoplasm.